Vice President - Corporate Development

Fortrea to acquire clinical pharmacology unit and bioanalytical laboratory operations from Worldwide Clinical Trials. September 02, 2026 Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Highlights * Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials * Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas * Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea's ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies * Strengthens Fortrea's end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence generation * Supports Fortrea's growth strategy through expanded scientific capabilities, increased early clinical development capacity and enhanced ability to create long-term value for shareholders * Supports Worldwide Clinical Trials' existing rapid global growth across oncology, neuroscience, internal medicine, and rare disease

WCG names Anthony Doyle chief financial officer to support growth. June 11, 2026 Anthony Doyle WCG has appointed Anthony Doyle as chief financial officer, effective June 15, 2026, adding a healthcare and clinical research finance executive as the company continues to expand its role in supporting clinical trial operations and decision-making. Doyle succeeds Robert VanHees, who will remain with WCG as a special advisor through Dec. 31, 2026, to support the transition. The leadership change comes as WCG seeks to strengthen financial operations, capital planning and organizational scale across its global clinical research platform. Doyle brings more than 20 years of financial leadership experience across healthcare, clinical research and both public and private equity-backed companies. He joins WCG from Flourish Research, a clinical trial site network, where he serves as chief financial officer. "Anthony brings a strong combination of financial rigor, operational leadership, and industry experience that aligns with WCG's strategic direction," said Sam Srivastava, chief executive officer of WCG. "He has a proven ability to scale finance organizations, lead complex capital strategies, and support high-growth businesses." Before joining Flourish Research, Doyle served as chief financial officer at BioCryst Pharmaceuticals and Worldwide Clinical Trials. In those roles, he led finance functions through periods of business expansion, operational transformation and capital strategy execution. Earlier in his career, he held finance leadership positions at General Electric, where he developed experience in operational finance, financial planning and analysis, and corporate development. His appointment comes as clinical research organizations and service providers face growing demand for technology-enabled solutions that can improve trial efficiency, reduce risk and support faster development timelines. As sponsors and research partners manage increasingly complex studies, companies such as WCG are expanding capabilities that combine regulatory oversight, data intelligence and operational support. WCG describes itself as a provider of clinical research decision infrastructure, helping organizations manage risk and make more confident decisions across the trial lifecycle. The company's work spans therapies at multiple stages of development, with a platform built around oversight, intelligence and data-driven support. Doyle said WCG's position in the clinical research ecosystem and its growth trajectory were key factors in his decision to join the company. "WCG plays a central role in advancing clinical research with a clear mission and a strong foundation for growth," Doyle said. "I'm excited to join the team and help drive disciplined execution, enable strategic investment, and support the company's continued momentum." Srivastava also credited VanHees for helping position the company for its next phase, noting his leadership and partnership over the past four years. The CFO transition reflects WCG's focus on scaling its financial and operational infrastructure as the company continues to serve pharmaceutical, biotechnology and clinical research partners. In a market increasingly shaped by data, artificial intelligence and pressure to improve trial performance, financial leadership is becoming central to how clinical research platforms invest, integrate capabilities and manage growth. With Doyle's appointment, WCG is adding an executive with experience across contract research, drug development and growth-stage healthcare organizations as it continues building its platform for clinical trial oversight and decision support.

Net Health acquired Keet Health from WebPT | Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research. Check out today's featured companies who have recently completed an M&A deal, and be sure to check out the full list of past healthcare IT M&A. Net Health Advances Rehab Therapy Care with Acquisition of Keet Health from WebPT Net Health, a trusted provider of specialized software for rehab therapy and post-acute care, today announced the acquisition of Keet Health, a WebPT company, as part of a strategic collaboration with WebPT focused on advancing outcomes measurement and remote therapeutic monitoring (RTM) for rehabilitation therapy providers. Net Health's acquisition of Keet Health expands access to Net Health's Limber platform - the industry's leading solution for outcomes measurement, RTM, and digital home exercise programs. In connection with the transaction, Limber will become the preferred outcomes and RTM solution for WebPT and Clinicient customers, with an integrated experience targeted for early 2026. "Better outcomes are driven by better insights and stronger connections across the continuum of care," said Ron Books, CEO at Net Health. "Through our collaboration with WebPT, we're advancing outcomes measurement and remote monitoring in ways that help rehab providers extend care beyond the clinic, reduce fragmentation, and keep the focus where it belongs - on patients." Limber, which Net Health acquired in 2025, is a leading platform for outcomes measurement, RTM enablement, and home exercise delivery for rehab therapy providers. The solution delivers outcomes-informed insights that help clinicians monitor progress, personalize care, and support patients beyond traditional clinic visits. Net Health continues to invest in Limber's analytics and integration capabilities as part of its broader platform strategy to support value-based care. Net Health and WebPT also plan to invest in deeper integration between Limber and the WebPT and Clinicient platforms. The integration is intended to streamline workflows, strengthen data continuity, and support more connected digital health experiences as patients transition between care settings. "Our work with Net Health gives our members access to a powerful digital health solution while preserving the flexibility and choice they expect," said Andrea Facini, CEO at WebPT... Full release here, originally announced January 15th, 2026. Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research Worldwide Clinical Trials, a global contract research organization (CRO), has entered into a definitive agreement to acquire Catalyst Clinical Research, LLC, a specialized oncology CRO, known for its expertise in early phase oncology trials and a strong biometrics and Functional Service Provider (FSP) model. Following the close of the transaction, Nick Dyer, Chairman of the Board at Catalyst, will join Worldwide's Board of Directors, and Nik Morton, President and CEO at Catalyst, will join Worldwide's executive leadership team. This strategic combination creates immediate value for customers by establishing Worldwide as a leading oncology-focused CRO, while maintaining depth across multiple therapeutic areas and strengthening its footprint and scale to deliver larger global trials. The integration of Catalyst's two established solutions - Catalyst Oncology and Catalyst Flex - will strengthen Worldwide's portfolio, offering customers proven expertise and new services for full-service, FSP resourcing, and hybrid solutions. Additionally, the integration of complementary technology platforms and best-in-class operational practices will enable enhanced data visibility and improved efficiency throughout the development lifecycle - helping customers bring life-changing therapies to patients more quickly. "Bringing Worldwide and Catalyst together elevates our capabilities in oncology and provides a new solution for our collective customers," said Alistair Macdonald, Chief Executive Officer at Worldwide. "We are excited to add Catalyst's deep operational expertise and oncology credibility to our own well-known CNS specialist CRO capabilities to create a differentiated biotech-oriented oncology solution. Our combined customers seek focused senior executive connection and attention, predictability, speed, flexibility, and scientific rigor. They will benefit from the addition of a scalable FSP model with integrated onshore/offshore service lines, while we leverage advanced business management tools and AI to drive operational excellence. Beyond the science, this is about people - bringing together talented teams, expanding opportunities, and working together to deliver more agile trials for our customers." Matt Jennings, Executive Chairman at Worldwide and Senior Operating Partner at Kohlberg, the majority owner of the Company, commented, "Integrating Catalyst will accelerate Worldwide's growth in oncology and expand both its customer base and global reach simultaneously. Their specialized expertise, innovative platforms, and strong relationships with emerging biotech sponsors align perfectly with our vision for building a differentiated, technology-enabled CRO. This is a strategic step toward creating a more agile and competitive organization that can meet the evolving needs of clinical research globally." "This marks an exciting new chapter for both Catalyst and Worldwide. By joining forces, Catalyst brings our specialized early phase oncology expertise together with Worldwide's strength in late phase development, expanding our global footprint and delivering differentiated oncology solutions globally," said Nik Morton, President and Chief Executive Officer at Catalyst... Full release here, originally announced January 20th, 2026.